The tweet was deleted by the author.
But we saved everything 🙂.
Camp4 Therapeutics Corp has announced the appointment of Michael MacLean to its Board of Directors. MacLean brings 35 years of expertise in financial and operational leadership to the company.
The appointment comes as Camp4 Therapeutics Corp advances its regRNA-based investigational therapy targeting SYNGAP1 toward clinical development. The company aims to leverage MacLean’s extensive industry experience as it navigates the transition from research to clinical trials.
Camp4 previously joined families at a SYNGAP1 Family Day event in Poland to share clinical updates with the patient community. The company has also presented its ASO platform for upregulating gene expression in SYNGAP1 and other diseases. These activities form part of Camp4's ongoing work to advance regRNA-based therapies.